Aleš Obr
Impact in
-
- Lymphoma Diagnosis and Treatment
- Oncology top 10%
- CAR-T cell therapy research
- Viral-associated cancers and disorders
Papers in
-
- Lymphoma Diagnosis and Treatment 18
- Oncology 13
- CAR-T cell therapy research 8
- Viral-associated cancers and disorders 4
- Co-authors
- Wojciech Jurczak (9 shared papers)Johannes Weirather (8 shared papers)Gianluca Gaïdano (8 shared papers)Sumeet Ambarkhane (8 shared papers)Maren Dirnberger‐Hertweck (8 shared papers)Gilles Salles (8 shared papers)Eva González‐Barca (8 shared papers)Johannes Duell (7 shared papers)
- Journals
- Blood (5 papers)Hematological Oncology (4 papers)Journal of Clinical Oncology (2 papers)Annals of Hematology (1 paper)Cancers (1 paper)
- Partner nations
- CzechiaUnited KingdomBelgium
In The Last Decade
Aleš Obr
20 papers receiving 476 citations
Aleš Obr's Hit Papers
Peers
Comparison fields: 5 of 41
- Pathology and Forensic Medicine 366
- Oncology 384
- Genetics 125
- Dermatology 42
- Immunology 74
Countries citing papers authored by Aleš Obr
This map shows the geographic impact of Aleš Obr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleš Obr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleš Obr more than expected).
Fields of papers citing papers by Aleš Obr
This network shows the impact of papers produced by Aleš Obr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleš Obr. The network helps show where Aleš Obr may publish in the future.
Co-authors
The 25 scholars most cited alongside Aleš Obr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study Hit paper breakdown → | 2020 | 324 |
| 2 | 2020 | 29 | |
| 3 | 2020 | 25 | |
| 4 | 2018 | 20 | |
| 5 | 2022 | 19 | |
| 6 | 2018 | 14 | |
| 7 | 2020 | 9 | |
| 8 | 2019 | 7 | |
| 9 | 2021 | 6 | |
| 10 | 2018 | 6 | |
| 11 | 2019 | 5 | |
| 12 | 2022 | 4 | |
| 13 | 2019 | 4 | |
| 14 | 2021 | 3 | |
| 15 | 2020 | 2 | |
| 16 | 2021 | 2 | |
| 17 | 2019 | 1 | |
| 18 | 2025 | 1 | |
| 19 | 2017 | 1 | |
| 20 | 2021 | 1 |
About Aleš Obr
Aleš Obr is a scholar working on Pathology and Forensic Medicine, Oncology, Genetics, Molecular Biology and Neurology, having authored 21 papers that have together received 483 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (11 papers), CAR-T cell therapy research (8 papers), Viral-associated cancers and disorders (4 papers), Protein Degradation and Inhibitors (3 papers), Lung Cancer Treatments and Mutations (2 papers), Cutaneous lymphoproliferative disorders research (2 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (366 citations), Oncology (384 citations), Genetics (125 citations), Dermatology (42 citations) and Immunology (74 citations). Aleš Obr has collaborated with scholars based in Czechia, United Kingdom and Belgium. Frequent co-authors include Wojciech Jurczak, Johannes Weirather, Gianluca Gaïdano, Sumeet Ambarkhane, Maren Dirnberger‐Hertweck, Gilles Salles, Eva González‐Barca, Johannes Duell, Kami J. Maddocks and Nagesh Kalakonda. Their work appears in journals such as Blood, Hematological Oncology, Journal of Clinical Oncology, Annals of Hematology and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.